Retrospective evaluation of patients with hairy cell leukemia: A decade experience at a single center

Basit Öğe Kaydı
dc.authorscopusid56789896800
dc.authorscopusid57193858564
dc.authorscopusid57209211885
dc.authorscopusid57205697036
dc.authorscopusid26030049400
dc.authorscopusid34571466800
dc.authorscopusid8599988500
dc.contributor.authorBaysal M.
dc.contributor.authorBas V.
dc.contributor.authorGulsaran S.K.
dc.contributor.authorOzdover A.C.
dc.contributor.authorUmit E.
dc.contributor.authorKırkızlar H.O.
dc.contributor.authorOzpuyan F.
dc.date.accessioned2024-06-12T10:26:35Z
dc.date.available2024-06-12T10:26:35Z
dc.date.issued2019
dc.description.abstractIn this study, we aimed to investigate the demographic characteristics, treatment modalities and response rates in patients with Hairy Cell Leukemia (HCL) which have been diagnosed and followed up in our center. Data of the 27 patients diagnosed with HCL at our center between 2007 and 2018 were retrospectively evaluated. Patients diagnosed with HCL according to WHO 2016 classification of lymphoid neoplasms by bone marrow biopsy. Flow cytometry, clinical and demographic data of the patients were evaluated. BRAFV600E mutational status evaluated in selected cases. All patients were given cladribine as first line treatment. Eight of our patients (29.6%) were female and 19 (70.3%) were male. In 20 patients (74%), complete remission was detected with first-line cladribine treatment, while in 3 patients (11.1%) partial remission was achieved, and 4 patients (14.8%) were unresponsive. Rituximab was administered to 3 refractory patients while one patient received pentostatine. Two patients who could not achieve remission died due to severe and critical infection, while one patient died due to cerebrovascular disease. 24 of our patients are still alive. Cladribine confers a safe and effective treatment modality. Although purine analogs have improved response rates and progression-free survival, progress has yet to be made for resistant and relapsing patients. © 2019, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.en_US
dc.identifier.doi10.5505/ejm.2019.67944
dc.identifier.endpage440en_US
dc.identifier.issn1301-0883
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85074456988en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage437en_US
dc.identifier.trdizinid332708en_US
dc.identifier.urihttps://doi.org/10.5505/ejm.2019.67944
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/332708
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16909
dc.identifier.volume24en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherYuzuncu Yil Universitesi Tip Fakultesien_US
dc.relation.ispartofEastern Journal of Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCladribine; Hairy Cell Leukemia; Real World Dataen_US
dc.subjectCladribine; Pentostatin; Rituximab; Adult; Article; Bone Marrow Biopsy; Cerebrovascular Disease; Clinical Article; Cytopenia; Death; Drug Safety; Female; Flow Cytometry; Follow Up; Hairy Cell Leukemia; Human; Human Tissue; Leukemia Remission; Lymphadenopathy; Male; Middle Aged; Mutation Rate; Overall Survival; Progression Free Survival; Retrospective Study; Splenomegaly; Treatment Responseen_US
dc.titleRetrospective evaluation of patients with hairy cell leukemia: A decade experience at a single centeren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu